Mark T. Osterman

4.6k total citations
157 papers, 3.2k citations indexed

About

Mark T. Osterman is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Mark T. Osterman has authored 157 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Genetics, 71 papers in Epidemiology and 70 papers in Surgery. Recurrent topics in Mark T. Osterman's work include Inflammatory Bowel Disease (94 papers), Microscopic Colitis (62 papers) and Eosinophilic Esophagitis (27 papers). Mark T. Osterman is often cited by papers focused on Inflammatory Bowel Disease (94 papers), Microscopic Colitis (62 papers) and Eosinophilic Esophagitis (27 papers). Mark T. Osterman collaborates with scholars based in United States, Belgium and Germany. Mark T. Osterman's co-authors include James D. Lewis, Gary R. Lichtenstein, Adam S. Cheifetz, Konstantinos Papamichael, Rabi Kundu, Colleen Brensinger, Ravy K. Vajravelu, Frank I. Scott, Lang Chen and Byron P. Vaughn and has published in prestigious journals such as Annals of Internal Medicine, Gastroenterology and Annals of the Rheumatic Diseases.

In The Last Decade

Mark T. Osterman

142 papers receiving 3.2k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark T. Osterman 2.1k 1.7k 781 707 517 157 3.2k
Bruce Salzberg 2.2k 1.0× 1.6k 1.0× 681 0.9× 835 1.2× 316 0.6× 39 2.8k
Mathurin Fuméry 2.2k 1.0× 1.7k 1.0× 1.0k 1.3× 788 1.1× 304 0.6× 198 3.3k
Κωνσταντίνος Κατσάνος 2.8k 1.3× 2.0k 1.2× 1.2k 1.5× 727 1.0× 516 1.0× 60 3.8k
Andrés Yarur 2.1k 1.0× 1.6k 1.0× 829 1.1× 652 0.9× 283 0.5× 161 2.9k
Miles Sparrow 2.0k 0.9× 1.3k 0.8× 642 0.8× 713 1.0× 847 1.6× 145 3.0k
Gottfried Novacek 1.8k 0.9× 1.6k 1.0× 1.2k 1.5× 387 0.5× 354 0.7× 103 3.3k
Fabiana Castiglione 2.3k 1.1× 1.9k 1.1× 1.3k 1.7× 426 0.6× 287 0.6× 144 3.6k
Ambrogio Orlando 2.5k 1.1× 2.7k 1.6× 1.2k 1.5× 591 0.8× 186 0.4× 152 4.5k
Waqqas Afif 2.0k 1.0× 1.7k 1.0× 775 1.0× 676 1.0× 254 0.5× 143 2.8k
Sang Hyoung Park 2.5k 1.2× 2.0k 1.2× 1.7k 2.2× 639 0.9× 385 0.7× 252 4.5k

Countries citing papers authored by Mark T. Osterman

Since Specialization
Citations

This map shows the geographic impact of Mark T. Osterman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark T. Osterman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark T. Osterman more than expected).

Fields of papers citing papers by Mark T. Osterman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark T. Osterman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark T. Osterman. The network helps show where Mark T. Osterman may publish in the future.

Co-authorship network of co-authors of Mark T. Osterman

This figure shows the co-authorship network connecting the top 25 collaborators of Mark T. Osterman. A scholar is included among the top collaborators of Mark T. Osterman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark T. Osterman. Mark T. Osterman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sands, Bruce E., David T. Rubin, Edward V. Loftus, et al.. (2025). Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial. The American Journal of Gastroenterology. 120(10). 2339–2349. 1 indexed citations
2.
Schreiber, Stefan, Brian G. Feagan, B E Sands, et al.. (2024). P545 Long-term efficacy of ozanimod up to 3 years in patient response subgroups identified using group-based trajectory modelling. Journal of Crohn s and Colitis. 18(Supplement_1). i1067–i1068. 1 indexed citations
3.
Danese, Silvio, Remo Panaccione, María T. Abreu, et al.. (2023). Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. Journal of Crohn s and Colitis. 18(2). 264–274. 26 indexed citations
4.
Vermeire, Séverine, J F Colombel, David T. Rubin, et al.. (2023). P715 Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension study. Journal of Crohn s and Colitis. 17(Supplement_1). i844–i845. 1 indexed citations
5.
Dignass, A, Miguel Regueiro, J F Colombel, et al.. (2023). DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients. Journal of Crohn s and Colitis. 17(Supplement_1). i110–i111. 4 indexed citations
6.
Vermeire, Séverine, J F Colombel, Michael Chiorean, et al.. (2023). P773 Extended induction in the True North open-label extension study: clinical outcomes of ~2 years of ozanimod treatment. Journal of Crohn s and Colitis. 17(Supplement_1). i903–i904. 2 indexed citations
7.
Dignass, A, Miguel Regueiro, J F Colombel, et al.. (2023). P687 Durability of recaptured response to ozanimod during the True North open-label extension. Journal of Crohn s and Colitis. 17(Supplement_1). i817–i818. 1 indexed citations
8.
Osterman, Mark T., Kelli L. VanDussen, Ilyssa O. Gordon, et al.. (2020). Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn’s Disease. Inflammatory Bowel Diseases. 27(5). 677–685. 9 indexed citations
9.
Bhattacharya, Abhik & Mark T. Osterman. (2020). Biologic Therapy for Ulcerative Colitis. Gastroenterology Clinics of North America. 49(4). 717–729. 37 indexed citations
10.
Lewis, James D., Frank I. Scott, Colleen Brensinger, et al.. (2018). Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. The American Journal of Gastroenterology. 113(3). 405–417. 109 indexed citations
11.
Osterman, Mark T., et al.. (2017). Clozapine-induced acute gastrointestinal necrosis: a case report. Journal of Medical Case Reports. 11(1). 270–270. 13 indexed citations
12.
Herfarth, Hans, Susan Jackson, Christopher Martin, et al.. (2016). Investigator-Initiated IBD Trials in the United States. Inflammatory Bowel Diseases. 23(1). 14–22. 17 indexed citations
13.
Zhang, Jie, Fenglong Xie, Huifeng Yun, et al.. (2016). Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 75(10). 1813–1818. 98 indexed citations
14.
Osterman, Mark T., Kevin Haynes, Elizabeth Delzell, et al.. (2015). Effectiveness and Safety of Immunomodulators With Anti–Tumor Necrosis Factor Therapy in Crohn’s Disease. Clinical Gastroenterology and Hepatology. 13(7). 1293–1301.e5. 56 indexed citations
15.
Scott, Frank I., Mark T. Osterman, Ryan McConnell, et al.. (2013). Impact of JC Virus Antibody Testing in Patients with Crohnʼs Disease with Loss of Response to Infliximab. Inflammatory Bowel Diseases. 19(12). 2625–2633. 1 indexed citations
16.
Forde, Kimberly A., Kevin Haynes, Andrea B. Troxel, et al.. (2011). Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population‐based cohort study*. Journal of Viral Hepatitis. 19(4). 271–277. 61 indexed citations
17.
Osterman, Mark T. & Gary R. Lichtenstein. (2009). Reformulation of an aminosalicylate: An example of the importanceof pill burden on medical compliance rates. Methods and Findings in Experimental and Clinical Pharmacology. 31(1). 41–41. 1 indexed citations
18.
Osterman, Mark T., et al.. (2008). Passive Smoking and Inflammatory Bowel Disease: A Meta-Analysis. The American Journal of Gastroenterology. 103(9). 2382–2393. 66 indexed citations
19.
Błoński, Wojciech, Rabi Kundu, James D. Lewis, et al.. (2008). Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis?. Scandinavian Journal of Gastroenterology. 43(6). 698–703. 39 indexed citations
20.
Osterman, Mark T. & Gary R. Lichtenstein. (2007). Current and future anti-TNF therapy for inflammatory bowel disease. Current Treatment Options in Gastroenterology. 10(3). 195–207. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bruce Salzberg Breakdown of academic impact, for papers by Mathurin Fuméry Breakdown of academic impact, for papers by Κωνσταντίνος Κατσάνος Breakdown of academic impact, for papers by Andrés Yarur Breakdown of academic impact, for papers by Miles Sparrow Breakdown of academic impact, for papers by Gottfried Novacek Breakdown of academic impact, for papers by Fabiana Castiglione Breakdown of academic impact, for papers by Ambrogio Orlando Breakdown of academic impact, for papers by Waqqas Afif Breakdown of academic impact, for papers by Sang Hyoung Park
Rankless by CCL
2026